| Home | Log In | Register | Our Services | My Account | Contact | Help |
Avacta Group plc (AVCT)
dreamcatcher
- 06 Jan 2013 09:27
Avacta Group plc, a UK-based healthcare technology and consumables business, provides innovative and proprietary solutions to the life sciences/healthcare sector through two operating divisions:
Avacta Analytical provides high-end analytical instrumentation and services to the biopharmaceutical sector, expected to be a US$200bn revenue market by 2013 and the fastest growing part of the pharmaceutical industry. The Company’s technologies are aimed at reducing the risks and expense associated with biological drug development and thereby reducing the final cost of drugs to patients. The Company’s lead analytical instrument, Optim, is distributed through Pall Corporation in US and SE Asia, Isogen Life Sciences in Europe, Cold Spring Biotech Corp in China and Taiwan and DKSH in Japan. Avacta sells Optim directly in the UK.
Avacta Animal Health provides diagnostic products and services for the US$1.5bn global veterinary diagnostics market. Its aim is to equip veterinary professionals with high quality animal health and well-being information through point of care diagnostics and laboratory based testing. Avacta’s AX-1 point of care immunoassay system is aimed at providing the veterinarian with rapid blood test results in the clinic. The initial range of tests launched with the AX-1 relates to Avacta’s world leading allergy testing brand Sensitest®. Avacta is developing further assays for the AX-1 system to diagnose a range of diseases in companion animals. Longer term, these technologies will be transferred into the human clinical diagnostics market.
Avacta joined AIM in August 2006 and is based in Wetherby, England.
http://www.avacta.com/
Bullshare
- 10 Oct 2017 09:46
- 62 of 64
The evening is a perfect opportunity for existing shareholders or potential investors to hear from those that matter, the directors running the companies and fund managers managing their fund. Who better to explain the future potential and strategy.
Thursday 19 October 2017
Venue:Novotel Tower Bridge, London EC3N 2NR, 10 Pepys Street, London, EC3N 2NR
Event Timings:| 18.00 | Registration and coffee | |
| 18.30 | Presentations • Alastair Smith, CEO - Avacta (AVCT) • Richard Shepherd-Cross, MD - Custodian REIT (CREI) • Peter Reynolds, Director, IR and Communications - Non-Standard Finance (NSF) • David Archer, CEO - Savannah Resources (SAV) • Stephen Blyth, CEO - Xpediator (XPD) | |
| 20.30 | Drinks reception and canapés | |
| 21.30 | Close |
 | Avacta’s focus is on its proprietary Affimer® platform technology, a novel engineered alternative to antibodies, that has wide application in diagnostics, therapeutics and research. Antibodies dominate markets worth more than $75bn despite their shortcomings. Affimer technology, based on a small, robust protein, can be quickly generated to bind with high specificity and affinity to a wide range of targets, addressing many of the limitations of antibodies. Avacta has a pre-clinical Affimer drug development programme with a focus on immuno-oncology as well as partnered development programmes. Avacta is commercialising non-therapeutic Affimer reagents through licensing to developers of research tools and diagnostics. |
 | Custodian REIT aims to be the Real Estate Investment Trust of choice for private and institutional investors seeking high and stable dividends from well-diversified UK real estate. Custodian REIT plc was launched as a main-market-listed, property investment company on the London Stock Exchange on 26 March 2014. The company was established with a seed portfolio of £95m and successful IPO, raising further 55m. Subsequent placings and considerable investment into UK regional real estate has seen the company grow to its current market capitalisation. The £95m seed portfolio was sourced from an existing portfolio of 48 properties, held by clients of Mattioli Woods and managed by Custodian Capital for the previous 12 years. Custodian Capital Limited is a subsidiary of Mattioli Woods plc. Custodian Capital is a property investment and management business, authorised and regulated by the Financial Conduct Authority (FCA). Their core business is acting as fund manager to Custodian REIT plc. |
 | NSF's businesses offer credit to the c.10 million UK adults not served by mainstream financial services businesses. Focused on branch-based lending, home credit and guaranteed loans, the Group’s goal is to deliver excellent customer outcomes and attractive returns for shareholders. Formed in 2014, Non-Standard Finance has become a leading provider of unsecured credit to UK adults. Listed on the Main Market of the London Stock Exchange (ticker: NSF) , we have around 100 locations servicing over 144,000 customers to whom we have outstanding loans of approximately £202m in aggregate. Our sizeable infrastructure is supported by around 600 full-time staff and 986 self-employed agents. |
 | AIM listed Savannah Resources Plc (AIM: SAV) is a multi-commodity development company focused on building cash generative and profitable mining operations. The Company operates a strategic portfolio of assets, spanning near term production potential and longer term development opportunities: • BLOCK 4 and 5 COPPER BLOCKS, OMAN – Awaiting mining licence - Production expected in H2 2018 (Blocks 4 and 5)• Jangamo / Mutamba Heavy Mineral Sands Project, Mozambique - being developed in partnership with mining major Rio Tinto with a view to building a dry mining operation• MINA DO BARROSO, PORTUGAL - opportunity to become the first lithium producer in Europe via fast-paced development strategy• Somero and Eräjärvi, Finland – early stage development potential over two highly prospective lithium projects |
 | Xpediator is the holding company for the Group, a well-established international provider of freight management services operating across the UK and Europe with a particular focus on, and expertise in, the CEE markets. he Group currently employs over 600 people with its operational headquarters in Braintree, England, and country offices in Bulgaria, Lithuania, Estonia, Macedonia, Montenegro, Moldova, Romania and Serbia operating from 22 sites in total. The Group has three main business areas which are managed autonomously on a day-to-day basis but directed centrally to cross-sell services to the Group’s customer base: - Freight forwarding, trading under the Delamode brand. - Logistics and warehousing, trading under the Delamode brand and EMT; and pallet distribution services, trading under the Pall-Ex brand. - Transport services, trading under the Affinity brand.
|
dreamcatcher
- 15 Nov 2017 18:03
- 63 of 64
RNS
RNS Number : 4911W
Avacta Group PLC
15 November 2017
15 November 2017
Avacta Group plc
("Avacta", "the Group" or "the Company")
Covance to Present Affimer Data at European Conference
Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, is pleased to announce that Covance will be presenting Affimer data from a joint study at the European Bioanalysis Forum 15-17 November 2017 in Barcelona.
Covance will be presenting data that highlights the validation of Affimer as a critical reagent in clinical assays when good batch-to-batch stability and reproducible performance are a regulatory requirement.
The work carried out collaboratively between Avacta and Covance shows that an Affimer assay to detect and quantify the breast cancer drug Trastuzumab shows good sensitivity and increased assay dynamic range compared to current existing antibody based assays.
The study demonstrates that Affimer reagents have the potential to be used as alternatives to antibodies and natural ligands as critical reagents in regulated assays in the development and batch release of therapeutic antibodies.
Dr Alastair Smith, Avacta Group Chief Executive Officer, commented:
"Presentation of Affimer data by our partners is strong, independent validation of the technical performance of Affimer reagents and is important to our commercialisation of the technology. The Group is delighted that the results of this work will be presented at this important European conference by Covance, a global contract research organization that that has worked on all of the top 50 best-selling drugs available today.
Reagents such as antibodies or ligand proteins, currently used in regulated bioanalysis of therapeutic proteins have their limitations. Cost and batch-to-batch variability is a serious and costly issue in critical assays. The work with Covance shows that Affimers can provide a rapid solution in such assays and additionally benefit from stability of supply.
We are now working to capitalise on the commercial opportunity that this presents and I look forward to updating the market on progress in due course."
dreamcatcher
- 15 Nov 2017 18:05
- 64 of 64
finnCap
200.00
Corporate
| About MoneyAM | Ts and Cs | Privacy Policy | Investment Warning | Content Standards | Corporate Solutions | Advertise With Us | Site Map | © 2025 MoneyAM |
Follow us on Twitter